Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam

Authors

Kathryn A. Connor, St. John Fisher UniversityFollow

Document Type

Article

Publication Date

10-2016

Keywords

fsc2017

Abstract

In lieu of an abstract, here is the article's first paragraph:

"A global crisis of antibiotic resistance is ongoing, especially with resistant gram-negative pathogens including Pseudomonas spp, carbapenemase-producing Enterobacteriaceae, and extended-spectrum β-lactamase (ESBL)-producing organisms. The increasing rate of methicillin-resistant Staphylococcus aureus (MRSA) infections is also a concern.¹ One newer intravenous cephalosporin (ceftaroline) was approved in 2010, and 2 new intravenous cephalosporin–β-lactamase inhibitor combinations (ceftolozane-tazobactam and ceftazidime-avibactam) have recently been approved to try to combat these resistant organisms in adult patients."

DOI

10.4037/aacnacc2016612

Comments

An overview of this research was presented at the 2017 Fisher Scholarship Celebration. This presentation is available under "Additional Files."

Publication Information

Connor, Kathryn A. (2016). "Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam." AACN Advanced Critical Care 27.4, 353-357.

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.